leisure time -WSS

leisure time

author：fashion 2025-09-27 22:49:49 - browse：644

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： A revolution in caring for preterm infants

WSS

A revolution in caring for preterm infants

Massive project maps cells in human brain in unprecedented detail

The biotech scorecard for Q3: 15 stock

Better Therapeutics data on benefit with GLP

European regulators consider appeal over Amylyx ALS drug

Lupron, used to halt puberty in children, may cause lasting health problems

entertainment

leisure time

Wikipedia

Hollywood unions extend contract negotiations for actors

What's changing in Medicare's open enrollment this year?

Heart attack and stroke risk calculators need revising

Undocumented workers face uncertainty as immigration law takes effect in Florida

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

'Screen and refer' systems are hurting patients

Walensky prepares to leave CDC — and Congress — behind

The wait for US passports is creating travel purgatory and snarling summer plans

Bright Health sells Medicare Advantage business to Molina

Cancer cells are shown to suck energy source from immune cells

focus

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

STAT Readout Newsletter: Today in biotech, life science news

STAT Readout Newsletter: Today in biotech, life science news

European regulators consider appeal over Amylyx ALS drug

Nick Jonas talks about managing diabetes along with his career

leisure time

Wikipedia

entertainment

focus